Detailed Narrative
Strong Q4 and FY25 Performance Driven by India Business
Alkem Laboratories reported a robust Q4 FY25 with total revenue from operations at Rs. 3,143.8 crores, marking a 7.1% YoY growth. India sales were a significant contributor, growing 8.1% YoY to Rs. 2,135.5 crores. For the full FY25, total revenue reached Rs. 12,964.5 crores, an increase of 2.3% YoY, while net profit surged 20.6% YoY to Rs. 2,165.5 crores, demonstrating strong execution.
EBITDA Margin Expansion and Future Outlook
The company achieved an EBITDA of Rs. 2,512.2 crores in FY25, representing an 11.9% YoY increase, leading to an EBITDA margin expansion from 17.7% in FY24 to 19.4%. Management guided for stable EBITDA margins of 19.5% for FY26, anticipating operating leverage from growth but also factoring in increased R&D investments. Gross margins for Q4 were lower due to specific factors like reduced production and absence of prior year settlement fees, but are expected to be around 63% or slightly better in FY26.
Strategic Investments in Biosimilar CDMO and MedTech
Alkem is actively investing in new growth avenues, with a biosimilar CDMO plant expected to be operational by Q2 FY26, having incurred Rs. 400 crores in capex in FY25. The company projects Rs. 100 crores in revenue from this CDMO business in FY26, with a potential to reach Rs. 450-500 crores over the next three years from full capacity utilization. However, these new ventures, including MedTech, are anticipated to result in combined operating losses of Rs. 100-125 crores in FY26 as they scale up.
Domestic Market Dynamics and Growth Strategy
While the India business showed strong Q4 growth, management acknowledged that certain segments like anti-infectives faced challenges, and the overall domestic market growth is influenced by the NLEM portfolio, where over 20% of products are under price control. Despite this, Alkem aims to outperform the market by at least 100 basis points, targeting an overall India market growth of 7-8% in FY26, driven by strong execution and targeted initiatives.
US and International Business Outlook
The US business is expected to achieve mid-single-digit growth in FY26, with plans to launch 5-6 new products. The company is closely monitoring litigation for high-value products like Entresto, with a potential launch as early as July (Q2 FY26). International business (excluding Americas) showed a 7.2% YoY growth in Q4 FY25, contributing Rs. 974.7 crores to revenue, with good traction in several key markets.
R&D and Tax Rate Guidance
R&D expenses for FY25 were Rs. 562 crores, or 4.3% of total revenue, and are guided to be around 5% for FY26 due to increased filings in non-US markets and a focus on complex oral solids and injectables for the US. The tax rate is guided at 13-15% for FY26, but is expected to rise to 35-38% in FY27 due to the utilization of MAT credit, before eventually settling at 25% post-utilization.
Acquisitions and Portfolio Expansion
Alkem completed acquisitions in MedTech (Bombay Ortho) and Dermatology (Adroit Biomed). Bombay Ortho is projected to generate Rs. 22-25 crores in revenue this year and Rs. 200 crores over five years, while Adroit Biomed, with a current turnover of Rs. 50 crores, is targeted for significant brand scaling, leveraging Alkem's geographical presence and focus on derma chronic segment.